KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash & Equivalents: 2015-2025

Historic Cash & Equivalents for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $4.0 billion.

  • BeOne Medicines' Cash & Equivalents rose 49.41% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year increase of 49.41%. This contributed to the annual value of $2.6 billion for FY2024, which is 17.16% down from last year.
  • BeOne Medicines' Cash & Equivalents amounted to $4.0 billion in Q3 2025, which was up 46.47% from $2.8 billion recorded in Q2 2025.
  • BeOne Medicines' 5-year Cash & Equivalents high stood at $4.5 billion for Q2 2022, and its period low was $1.4 billion during Q3 2021.
  • Moreover, its 3-year median value for Cash & Equivalents was $2.8 billion (2024), whereas its average is $3.0 billion.
  • Per our database at Business Quant, BeOne Medicines' Cash & Equivalents soared by 216.63% in 2021 and then dropped by 26.92% in 2023.
  • Over the past 5 years, BeOne Medicines' Cash & Equivalents (Quarterly) stood at $4.4 billion in 2021, then decreased by 11.57% to $3.9 billion in 2022, then fell by 18.03% to $3.2 billion in 2023, then decreased by 17.16% to $2.6 billion in 2024, then skyrocketed by 49.41% to $4.0 billion in 2025.
  • Its Cash & Equivalents was $4.0 billion in Q3 2025, compared to $2.8 billion in Q2 2025 and $2.5 billion in Q1 2025.